Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Over 3 fiscal years it widened by 4835.7 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-91.0%+951.5 pp YoY
LTMMar 2026
-80.4%+881.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+951.5 pp——
3 years+4835.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-91.0%
Year-over-year change
+951.5pp

Gross Margin vs competitors

How INBX compares with its peers on the latest reported figures

  • INBX's LTM Mar 2026 gross margin of -80.4% is the 4th highest of the 6 companies compared; the peer median is 54.1%.
  • Its year-over-year change of +881.6 pp is the 2nd highest of 6, against a peer median of +0.1 pp.
  • Over three fiscal years its change of +4835.7 pp compares with a peer median of +333.7 pp.
INBX Competitors Peer median
Gross Margin for INBX and competitors
Company Period LTM level YoY 3-year change
GENBGenerate Biomedicines, Inc.FY2025100.0% +0.0 pp—
IMTXImmatics N.V.LTM Mar 2026100.0% +0.1 pp+61.8 pp
JANXJanux Therapeutics, Inc.LTM Mar 202654.1% +476.2 pp-10.5 pp
INBXInhibrx Biosciences, Inc.LTM Mar 2026-80.4% +881.6 pp+4835.7 pp
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-662.5% +5797.5 pp+3489.9 pp
ABSIAbsci CorporationLTM Mar 2026-1316.9% -337.8 pp+605.7 pp
TECXTectonic Therapeutic, Inc.FY2025— ——
Peer median (excluding INBX) 54.1%+0.1 pp+333.7 pp

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.13M2.19M1.8M200K1.3M
Cost of Revenue2.69M110.19M1.19M2.29M2.48M
Gross Profit4.44M(107.99M)609K(2.09M)(1.18M)
Gross Margin62.3%-4926.7%33.8%-1042.5%-91.0%
Research & Development71.44M110.19M190.65M203.74M113.03M
Selling, General & Admin12.36M21.12M29.38M127.91M23.3M
Operating Expenses12.34M21.12M219.83M329.36M133.84M
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
EBITDA(75.37M)(125.82M)(206.69M)1.7B(132.54M)
EBITDA Margin-1057.8%-5739.8%-11482.9%851675.0%-10195.5%
Operating Income(76.56M)(129.12M)(219.22M)(331.45M)(135.03M)
Operating Margin-1074.6%-5890.4%-12178.9%-165724.0%-10386.5%
Interest Income5.22M16.11M11.92M10.94M7.55M
Interest Expense5.22M16.11M31.84M13.49M12.2M
Other Income / Expenses(5.2M)(16.11M)(20.5M)2.02B(5.03M)
Income Before Tax(81.77M)(145.22M)(239.72M)1.69B(140.05M)
Pre-Tax Margin-1147.6%-6625.1%-13318.0%843787.0%-10773.3%
Income Tax Expense2K3K3K2K2K
Net Income(81.77M)(145.23M)(241.36M)1.69B(140.06M)
Net Margin-1147.6%-6625.3%-13408.9%843786.0%-10773.5%
EPS (Basic)(2.15)(3.62)(5.12)116.58(9.04)
EPS (Diluted)(2.15)(3.62)(5.12)116.58(9.04)
Weighted Avg Shares38.01M40.11M47.13M14.48M15.49M
Weighted Avg Shares (Diluted)38.01M40.11M47.13M14.48M15.49M

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.